Related Experiment Video
Updated: Jun 30, 2025
Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
Published on: September 9, 2020
Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy
J Chase Cole1, Samantha F Benvie2, Marci DeLosSantos1
1Department of Pharmacy, University of Florida Health-Jacksonville, Jacksonville, Florida.
Insights
Mavacamten offers a new, targeted treatment for hypertrophic cardiomyopathy (HCM), improving symptoms and exercise capacity in patients with obstructive HCM. This novel therapy may reduce the need for invasive procedures.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease causing significant morbidity and mortality.
- Previous treatments for HCM were not disease-specific and often poorly tolerated.
- Limited therapeutic options existed for patients with persistent HCM symptoms.
Purpose of the Study:
- To review the pharmacology of mavacamten, a novel drug for hypertrophic cardiomyopathy.
- To discuss clinical trials supporting the use of mavacamten in HCM management.
- To outline considerations for the clinical application of mavacamten.
Main Methods:
- Literature search of PubMed and ClinicalTrials.gov for mavacamten and Camzyos (January 2015-March 2023).
- Inclusion of data from key clinical trials: EXPLORER-HCM and VALOR-HCM.
- Exclusion of non-randomized, controlled trials.
Main Results:
- Mavacamten demonstrated efficacy in treating symptomatic obstructive HCM.
- Treatment with mavacamten improved exercise capacity and New York Heart Association functional class.
- Mavacamten use was associated with reduced left ventricular outflow tract obstruction and decreased need for septal reduction therapy.
Conclusions:
- Mavacamten represents a novel therapeutic option for patients with HCM.
- It offers improved outcomes for those with persistent symptoms and obstructive HCM.
- Future trials may expand mavacamten's indication to nonobstructive HCM.
Purpose:
Hypertrophic cardiomyopathy (HCM) is an under-recognized genetic cardiac disorder affecting the muscles and contractility of the heart, which in turn can result in heart failure symptoms, arrhythmia, and sudden cardiac death. Previously, pharmacotherapy options for HCM were not disease-specific, often poorly tolerated, and overall inadequate for optimal management. This narrative review discusses the pharmacology of the novel drug mavacamten, the clinical trials supporting its use, and considerations for its use in clinical practice.
Methods:
PubMed and ClinicalTrials.gov were searched for the key words mavacamten and Camzyos to identify currently active clinical trials and clinical trials published between January 2015 and March 2023. Data from EXPLORER-HCM were included, as EXPLORER-HCM led to approval by the US Food and Drug Administration of the use of mavacamten, along with data from VALOR-HCM, which provided additional evidence for use. Publications that were not randomized, controlled trials were not included in this review.
Findings:
The findings from this review suggest that mavacamten is an effective treatment for patients with persistently symptomatic obstructive HCM and may decrease the need for septal reduction therapy. Mavacamten use was associated with improved exercise capacity, left ventricular outflow tract obstruction, and New York Heart Association functional class, and with a decreased frequency of septal reduction therapy.
Implications:
HCM is associated with significant morbidity and mortality, independent of other disease states. Mavacamten is a novel treatment option for patients with HCM and offers an additional option for patients with persistent symptoms who previously had limited treatment options. The use of mavacamten in patients with obstructive HCM may improve exercise capacity, and decrease symptoms and the need for septal reduction therapy. There is potential for mavacamten to be indicated for use in patients with nonobstructive HCM in the future, pending findings from Phase III trials in this population.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Heart Failure Drugs: Inotropic Agents
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:22Heart Failure Drugs: β-Blockers